The purpose of this CME activity is to improve the knowledge base and clinical proficiency of GI, pancreatic cancer, GI oncology, general oncology, surgical oncology, GI oncology fellows, and neuroendocrine tumor medicine specialists, and others managing patients with metastatic pancreatic cancer. Accordingly, it will address new advances in staging and assessment of patients, therapeutic developments, guidelines, clinical trial data, translational implications, and multimodal strategies that address the unmet clinical and therapeutic challenges posed by complex patients with pancreatic adenocarcinoma and pancreatic neuroendocrine tumors (panNET).

 

This program will enlist leading U. S. authorities on metastatic pancreatic cancer, including both pancreatic adenocarcinoma and pancreatic neuroendocrine tumors (panNET). It will be structured and developed to produce and communicated scientifically rigorous, evidence-​based, and expert-​generated information and education concentrating on landmark advances, new paradigms, national guidelines, and emerging diagnostic and therapeutic strategies that have been shown safe and effective in the treatment of pancreatic adenocarcinoma and pancreatic neuroendocrine tumors (panNET).

 

The activity will focus on strategies to optimize survival outcomes, improve symptoms and quality of life, and minimize disease progression using therapies that are evidence-​based and supported by clinical trials and expert analysis.







 


If you have any questions, please call 1-​866-​912-​4726.

Joint Providership by the University of Massachusetts Medical School, Office of CME and CMEducation Resources, LLC

Funded by an independent educational grant from Ipsen.